<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03471039</url>
  </required_header>
  <id_info>
    <org_study_id>H-17016232</org_study_id>
    <nct_id>NCT03471039</nct_id>
  </id_info>
  <brief_title>PACAP27 Headache Properties in Migraine Without Aura Patients</brief_title>
  <official_title>Pituitary Adenylate Cyclase-activating Polypeptide (PACAP27) Headache Properties in Migraine Without Aura Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pituitary adenylate cyclase-activating polypeptide (PACAP) is a signaling molecule, localized
      in sensory and parasympathetic perivascular nerves fibres. PACAP exists i to functional
      iso-forms Pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) and PACAP27.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 30, 2017</start_date>
  <completion_date type="Actual">September 30, 2018</completion_date>
  <primary_completion_date type="Actual">August 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache Scores</measure>
    <time_frame>0-12 hours</time_frame>
    <description>Comparison between PACAP27 and Placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Facial blood flow (flushing)</measure>
    <time_frame>0-120 mins</time_frame>
    <description>PACAP27 induces facial flushing compare to placebo measured by laser speckle contrast imaging</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Migraine Without Aura</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PACAP-27</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PACAP27</intervention_name>
    <description>Infusion of PACAP27 over 20 minutes.</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Infusion of Saline over 20 minutes.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Migraine patients meeting International Headache Society (IHS) criteria for migraine
             without aura of both sexes, 18-60 year, 50-100 kg.

               -  Fertile women should use safe contraception. Fertile women do not include
                  hysterectomized women or women who are postmenopausal for at least 2 years. Safe
                  contraception includes either Intra Uterine Device (IUD), birth control pills,
                  surgical sterilization of the woman or depot progestogen.

        Exclusion Criteria:

          -  Tension Type headache for more than 5 days the month on average in the last year.

               -  All other primary headaches .

               -  Headache later than 48 hours before trial start.

               -  Daily intake of any medicine other than oral contraception.

               -  Ingestion of any form of medicinal product later than 4 times the plasma
                  half-life substance (on trial day), except for oral contraception.

               -  Pregnant or breastfeeding women.

               -  Headache on the test day or later than 48 hours prior to administration of trial
                  medicine / placebo

               -  Migraine within 5 days before the trial date.

               -  Ancestral information or clinical signs of (on the day of inclusion):

          -  Hypertension (systolic blood pressure&gt; 150 mmHg and / or diastolic blood pressure&gt; 100
             mmHg)

          -  Hypotension (systolic blood pressure &lt;90 mm Hg and / or diastolic blood pressure &lt;50
             mmHg)

               -  Cardiovascular disease of all kinds, including cerebrovascular disease.

               -  Anamnestic or clinical signs of mental illness or abuse.

               -  Patients with glaucoma or prostatic hyperplasia

               -  Anamnestic or clinical signs of diseases of any kind such as the investigating
                  physician is considered relevant for participation in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Danish Headache Center</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2018</study_first_posted>
  <last_update_submitted>January 23, 2019</last_update_submitted>
  <last_update_submitted_qc>January 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Hashmat Ghanizada</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine without Aura</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Adenylate Cyclase-Activating Polypeptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

